Impact of COVID-19 on Neuropsychiatric Disorders

Niloufar Zia; Parsa Ravanfar; Sepideh Allahdadian; Mehdi Ghasemi

doi:10.3390/jcm11175213

Impact of COVID-19 on Neuropsychiatric Disorders

J Clin Med. 2022 Sep 3;11(17):5213. doi: 10.3390/jcm11175213.

Authors

Niloufar Zia¹, Parsa Ravanfar², Sepideh Allahdadian³, Mehdi Ghasemi⁴

Affiliations

¹ Department of Psychology, Lesley University, Cambridge, MA 02138, USA.
² Department of Psychiatry, University of Texas Southwestern, Dallas, TX 75390, USA.
³ Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
⁴ Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.

Abstract

Since the Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many studies have shown that besides common COVID-19 symptoms, patients may develop various neuropsychiatric conditions including anxiety, mood disorders, psychosis, neurodegenerative diseases (e.g., dementia), insomnia, and even substance abuse disorders. COVID-19 can also worsen the patients underlying neuropsychiatric and neurodevelopmental conditions during or after the system phase of disease. In this review, we discuss the impact of SARS-CoV-2 infection on development or status of neuropsychiatric conditions during or following COVID-19.

Keywords: coronavirus disease 2019 (COVID-19); neurodegenerative diseases; neurodevelopmental diseases; neuropsychiatry; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Publication types

Review

Grants and funding

M.G. is supported by a clinical research training scholarship in ALS funded by The ALS Association and The American Brain Foundation, in collaboration with the American Academy of Neurology as well as NIH-funded Wellstone fellowship training grant (NIH 5P50HD060848-15) for research on FSHD.